Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0001260
UniProt IDQ9UQL6
Primary gene name(s)HDAC5
Synonym gene name(s)KIAA0600
Protein nameHistone deacetylase 5
Protein functionResponsible for the deacetylation of lysine residues on the N-terminal part of the core histones, H2A, H2B, H3 and H4. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation by repressing transcription of myocyte enhancer MEF2C. During muscle differentiation, it shuttles into the cytoplasm, allowing the expression of myocyte enhancer factors. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. {ECO:0000269|PubMed:24413532}.
Subcellular locationNucleus. Cytoplasm. Note=Shuttles between the nucleus and the cytoplasm. In muscle cells, it shuttles into the cytoplasm during myocyte differentiation. The export to cytoplasm depends on the interaction with a 14-3-3 chaperone protein and is due to its phosphorylation at Ser-259 and Ser-498 by AMPK, CaMK1 and SIK1.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q9UQL6
Gene Ontology
(Biological Process)
Complete annatation
B cell activation [GO:0042113];
B cell differentiation [GO:0030183];
cellular response to insulin stimulus [GO:0032869];
cellular response to lipopolysaccharide [GO:0071222];
chromatin organization [GO:0006325];
chromatin remodeling [GO:0006338];
chromatin silencing [GO:0006342];
histone deacetylation [GO:0016575];
inflammatory response [GO:0006954];
negative regulation of cell migration involved in sprouting angiogenesis [GO:0090051];
negative regulation of myotube differentiation [GO:0010832];
negative regulation of transcription, DNA-templated [GO:0045892];
negative regulation of transcription from RNA polymerase II promoter [GO:0000122];
neuron differentiation [GO:0030182];
positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091];
positive regulation of transcription from RNA polymerase II promoter [GO:0045944];
protein deacetylation [GO:0006476];
regulation of gene expression, epigenetic [GO:0040029];
regulation of myotube differentiation [GO:0010830];
regulation of protein binding [GO:0043393];
response to activity [GO:0014823];
response to cocaine [GO:0042220];
response to drug [GO:0042493];
transcription, DNA-templated [GO:0006351]
Gene Ontology
(Molecular Function)
Complete annatation
chromatin binding [GO:0003682];
core promoter binding [GO:0001047];
histone deacetylase activity [GO:0004407];
histone deacetylase binding [GO:0042826];
metal ion binding [GO:0046872];
NAD-dependent histone deacetylase activity, H3-K14 specific [GO:0032041];
protein deacetylase activity [GO:0033558];
protein kinase C binding [GO:0005080];
repressing transcription factor binding [GO:0070491];
RNA polymerase III transcription factor binding [GO:0001025];
transcription factor binding [GO:0008134]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
Golgi apparatus [GO:0005794];
histone deacetylase complex [GO:0000118];
nucleoplasm [GO:0005654];
nucleus [GO:0005634]
Protein-protein interaction115331
Phylogenetic treeQ9UQL6
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-0.4326419728402440.1890373985534220.291923326946432
AZA vs. DISU0.8719299483076890.0007109266024916130.0598410812401494
AZA vs. IL7-0.9093754764187153.87615206620673e-060.00139107714509367
AZA vs. SAHA0.3293249384297710.1794274207498390.540930887494033
DISU vs. CD31.291350591895040.0005752228973209260.00257068187198803
DISU vs. IL7-1.791147189265886.71805278074089e-102.59678578640177e-07
DISU vs. SAHA-0.5402968491136570.06616304372838070.325393954007024
DMSO vs. AZA0.004006313114890680.9811495192513641
DMSO vs. CD30.4207679958917210.1908782734457940.288192141657735
DMSO vs. DISU-0.8709489802879520.0004514509662157940.0412325215810425
DMSO vs. IL7-0.9056303126752668.8427738809127e-070.000310011200592463
DMSO vs. SAHA0.3209139421892230.1756148017161140.506543670174844
HIV vs. Mock in Activation0.2881174098610730.6461338973366660.999983755607037
HIV vs. Mock in Latency0.2273695175897890.1740633970064790.999834320637052
IL7 vs. CD3-0.4712563886274480.149203479808490.257995187696842
SAHA vs. CD30.7381350552550640.03863859987803060.0801712378028255
SAHA vs. IL71.235347368203076.98711277835606e-073.32251539498231e-05
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.398571 0.00879669
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.03 0.903 0.928 0.915 0.752
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB05015 Belinostat approved, investigational yes inhibitor
DB06603 Panobinostat approved, investigational yes inhibitor

Protein Secondary Structure       (annotations from PDB)      top

not found

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa05034 Alcoholism - Homo sapiens (human)
hsa05169 Epstein-Barr virus infection - Homo sapiens (human)
hsa05203 Viral carcinogenesis - Homo sapiens (human)